A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Wang CX, Luxardi G, Mori H, Maverakis EM, Merleev AA, Marusina AI, Borowsky AD, Parikh M, Riess JW, Moshiri A, Bazhenova L, Gubens M, Koczywas M, Butner JD, Huang J, Kim SK, Vick LV, Sun Y, Canter RJ, Murphy WJ, Daly ME, Kelly K, Monjazeb AM

Open source

DOI: 10.1080/2162402x.2026.2695491
Published: 2026 Dec 31
Container: Oncoimmunology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/2162402x.2026.2695491,
  title = {A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.},
  author = {Wang CX and Luxardi G and Mori H and Maverakis EM and Merleev AA and Marusina AI and Borowsky AD and Parikh M and Riess JW and Moshiri A and Bazhenova L and Gubens M and Koczywas M and Butner JD and Huang J and Kim SK and Vick LV and Sun Y and Canter RJ and Murphy WJ and Daly ME and Kelly K and Monjazeb AM},
  year = {2026},
  journal = {Oncoimmunology},
  doi = {10.1080/2162402x.2026.2695491},
  url = {https://doi.org/10.1080/2162402x.2026.2695491}
}

RIS

TY  - JOUR
TI  - A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.
AU  - Wang CX
AU  - Luxardi G
AU  - Mori H
AU  - Maverakis EM
AU  - Merleev AA
AU  - Marusina AI
AU  - Borowsky AD
AU  - Parikh M
AU  - Riess JW
AU  - Moshiri A
AU  - Bazhenova L
AU  - Gubens M
AU  - Koczywas M
AU  - Butner JD
AU  - Huang J
AU  - Kim SK
AU  - Vick LV
AU  - Sun Y
AU  - Canter RJ
AU  - Murphy WJ
AU  - Daly ME
AU  - Kelly K
AU  - Monjazeb AM
PY  - 2026
JO  - Oncoimmunology
DO  - 10.1080/2162402x.2026.2695491
UR  - https://doi.org/10.1080/2162402x.2026.2695491
ER  -

APA

CX, W., G, L., H, M., EM, M., AA, M., AI, M., AD, B., M, P., JW, R., A, M., L, B., M, G., M, K., JD, B., J, H., SK, K., LV, V., Y, S., RJ, C., WJ, M., ME, D., K, K., & AM, M. (2026). A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.. Oncoimmunology. https://doi.org/10.1080/2162402x.2026.2695491

Source records

pubmed · retrieved 2026-09-25T17:57:01.104Z
europe-pmc · retrieved 2026-09-25T17:57:01.144Z
doaj · retrieved 2026-09-25T17:57:01.111Z